Research advance of Lambert-Eaton myasthenic syndrome and its corresponding therapies
LIU Shi-peng
FENG Wen-hua
Abstract：Lambert-Eaton myasthenic syndrome (LEMS) is a rare human autoimmune disorder of the neuromuscular junction.With the difference from myasthenia gravis caused by the interaction between acetylcholine receptor and its relevant antibodies,LEMS is closely related with P/Q voltage-gated calcium channel antibodies existing in the serum.These antibodies can impair the release of acetylcholine in the presynaptic membrane and consequently give rise to a series of clinical symptoms.This article systematically describes the epidemiology,pathogenesis,and clinical diagnosis of LEMS,and explains the treatment and the basic information of drugs,with a view to help clinical therapy and drug research in the future.Amifampridine phosphate,an important drug for LEMS,is a potassium channel blocker.It blocks the potassium channel on the neuronal membrane,and then increases the opening time of the calcium channel,finally results in releasing more acetylcholine,which makes it the top preference for the treatment of LEMS.
Keywords：Lambert-Eaton myasthenic syndromevoltage-gated calcium channelsneuromuscular junctionamifampridine phosphate
Publication Date：2017-01-01
Online Publishing Date：2026-08-14(First online date of this platform, not the publication date of the document)
Pages：5( 1279-1283 )